New plasmonic isothermal PCR technology can detect respiratory viral pathogens in 30 minutes

Researchers in South Korea developed a plasmonic isothermal recombinase polymerase amplification (RPA) array chip, the world's first plasmonic isothermal PCR technology which can detect 8 types of pathogens (4 bacteria and 4 viruses) that cause acute respiratory infectious diseases in 30 minutes, led by Dr. Sung-Gyu Park and Dr. Ho Sang Jung of the Korea Institute of Materials Science (KIMS, President Jung-Hwan Lee) and by Dr. Min-Young Lee and Dr. Ayoung Woo of Samsung Medical Center. KIMS is a government-funded research institute under the Ministry of Science and ICT.

The current detection technology for COVID-19 is impossible to analyze on-site as it takes about 4 hours or more to be confirmed after specimen collection, making it difficult to isolate the infectee as soon as possible.

To solve this problem, the researchers combined isothermal PCR technology with 3D Au nanostructured substrate which can amplify the fluorescence signal of RPA products with DNA amplicons and sucessfully detected bacterial DNA and viral RNA within 30 minutes.

In addition, the research team also developed a 3D plasmonic array chip for multiplex molecular detections: a chip that can simultaneously analyze 8 pathogens (4 bacteria and 4 viruses).

The "multiplex diagnosis technology for acute respiratory infections" was also confirmed to be valid for clinical specimens collected by nasopharyngeal swabs. The team is planning to perform the reliability test of medical devices through large-scale clinical trials on COVID-19 infectees and applying for approval from the Ministry of Food and Drug Safety.

The "3D plasmonic nanomaterials technology for enhancing optical signal" of KIMS has already been patented in Korea, the US, and China, and the "on-site rapid pathogen detection technology" has been applied for a domestic patent jointly with Samsung Medical Center.

"We developed a medical device that can detect pathogens in half an hour on-site, by developing core plasmonic nanomaterials which enable ultra-sensitive pathogene diagnosis of more than 10 types of respiratory viral pathogens. The on-site molecular diagnostic devices can be prevalent rapidly as we actively research with Samsung Medical Center and domestic diagnostic device companies." said Dr. Sung-Gyu Park, a principal research scientist of KIMS.

KIMS consistently supports to commercialize the on-site molecular diagnosis technology for respiratory infectious disease and ultrasensitive drug detection sensor technology which are based on the 3D highly sensitive plasmonic nanomaterials. We will do our utmost so that our research outcomes contribute to the quality of life and safe society."

Jung-hwan Lee, President, KIMS

This research was supported by the Fundamental Research Program of the Korea Institute of Materials Science (KIMS) and funded by Nano Plasmonic In Vitro Diagnostic Research Center of the Ministry of Science and ICT, and the alchemist project of the Ministry of Trade, Industry and Energy.

Also, the technology was published in Biosensors and Bioelectronics (IF:10.257), the principal international journal in the field of analytical chemistry.

The research team was selected as a national R&D excellence in 2020 by developing an ultra-sensitive detection sensor for sepsis through a 3D nano-biosensor chip.

Source:
Journal reference:

Woo, A., et al. (2021) Rapid and sensitive multiplex molecular diagnosis of respiratory pathogens using plasmonic isothermal RPA array chip. Biosensors and Bioelectronics. doi.org/10.1016/j.bios.2021.113167.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into respiratory syncytial virus and prevention strategies